News archive

Latest news

18 Jul 2023

Invitation to Idorsia's HY 2023 Financial Results webcast and conference call

26 Jun 2023

New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023

23 Jun 2023

New Phase 3 data with aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2023

12 Jun 2023

Idorsia launches QUVIVIQ (daridorexant) in Switzerland – a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning

04 May 2023

Idorsia holds its Annual General Meeting of Shareholders

03 May 2023

Health Canada approves QUVIVIQ (daridorexant) for the management of adult patients with insomnia

06 Apr 2023

Idorsia issues invitation to the 2023 Annual General Meeting of Shareholders

17 Mar 2023

On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder

31 Jan 2023

Idorsia submits European marketing authorisation application for aprocitentan for the treatment of patients with resistant hypertension

20 Dec 2022

Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension

15 Dec 2022

Idorsia initiates OPUS a Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus

12 Dec 2022

Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs

05 Dec 2022

Swissmedic approves QUVIVIQ (daridorexant) – a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning

15 Nov 2022

QUVIVIQ (daridorexant) – Europe’s first dual orexin receptor antagonist – is now available for patients with chronic insomnia disorder in Italy and Germany

13 Nov 2022

Idorsia congratulates its Chief Scientific Officer Martine Clozel who has been honored by Initiative Switzerland with the Annual Prix Suisse Award

07 Nov 2022

The Lancet and AHA late-breaking science session reports significant and sustained effect of aprocitentan on lowering blood pressure for patients with resistant hypertension

10 May 2022

Phase 2a study results in binge eating disorder

03 May 2022

Europe’s first dual orexin receptor antagonist – QUVIVIQ (daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder

02 May 2022

Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia

20 Apr 2022

PIVLAZ (clazosentan) – Idorsia’s first commercial product – now available for patients in Japan

Ad hoc announcements pursuant to Art. 53 LR

Ad hoc announcements pursuant to Art. 53 LR have been classified from 2021 onwards. A full archive of press releases can be found under the "All" tab.

News in German

As a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland, we have many people interested in reading more about the company in German.

Read selected news in German